The future home of the UTC School of Nursing, the Dorothy and Jim Kennedy Health Sciences Building, broke ground on Monday. Located at the corner of Palmetto and East 3rd streets, this new ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate of ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in the year-ago quarter. The figure was wider than the Zacks Consensus ...

Exact Sciences Corp ( (EXAS)) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors. Exact Sciences Corp. is a prominent company in ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...